Dishman Pharmaceuticals and Chemicals (Dishman), a leading global manufacturer of pharmaceutical active ingredients, has received a license agreement from Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) to produce the Active Pharmaceutical Ingredient (API) of SIRTURO (bedaquiline), a medicine used in the treatment of Multi-Drug Resistant Tuberculosis (MDR-TB).
Tuberculosis (TB) is a major public health concern in India with the World Health Organization estimating there are more than 2.8 million cases of TB. In particular, the burden of MDR-TB in India, is among the most significant in the world with an estimated 64,000 cases, and for those diagnosed with this deadly disease, fewer than half are treated successfully. In 2008 Janssen had contracted Dishman to conduct full chemical synthesis of this API at their manufacturing facility in Bavla, India. Janssen subsequently registered Dishman as a manufacturer of API with the USFDA, European Medicines Agency and several other Asian regulatory authorities. Recently, Dishman has started supplying Janssen with the global demand of this API.
Dishman is a leading global outsourcing partner for the pharmaceutical industry, offering a rich portfolio of development, scale-up and manufacturing services that straddle the entire pharmaceutical value chain. The company offers cost-effective, high-quality research, development and manufacturing services that include production and supply of tailor-made, high-quality Intermediates and generic APIs to the global pharmaceutical industry. Its global presence includes multiple manufacturing sites in Europe, India, and China - making it one of the most geographically diversified players in the industry.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: